Lixte Biotechnology Holdings Inc (LIXT) USD0.0001

- Add to watchlist
- This stock can be held in a




Business summary
Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has the therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The Company has developed two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series consists of structures, which is treated not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which are useful for the treatment of chronic hereditary diseases.
Contact details
Important dates
General stock information
- Short code:
- LIXT
- ISIN:
- US5393192027
- Market cap:
- $12.18 million
- Shares in issue:
- 16.65 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.